1/57
Looks like no tags are added yet.
what are viruses
intracellular parasites that need a host to survive
AIDs is caused by
HIV
Tx of HIV infection
highly active antiretroviral therapy (HAART)
PEP
post exposure prevention
- occupational, needle stick, blood or mucus exposure
-non occupational, mother to infant, and sex
PrEP
pre-exposure prevention
- those with ongoing high risk
PrEP: truvada
emtricitabine + tenofovir disoproxil
2012
PrEP
emtricitabine + tenofovir alafenamide
2019
men and transgender women
HIV Life cycle
binding/fusion with host CD4 cells
reverse transcriptase
integration
transcription
virion assembly
budding
HIV binds and enter ___ cells
CD4
what was the 1st HIV agent
zidovudine 1987
antiviral classes
entry inhibitors
NRTI
NNRTI
protease inhibitors
integrase inhibitors
nucleoside
base + sugar
nucleotide
base + sugar + phosphate
what was the new drug in 2022
lenacapavir
capsid inhibitor
how does HIV enter host cell
virus binds to cd4 receptor on T cell
gp120/cd4 complex significant changes
gp120 binds to CCR5 more changes
exposure of gp120 fusion of viral envelop in host cell
entry inhibitor: maraviroc
binds to CCR5 on T cell
entry inhibitor: enfuvirtide 2003
binds to gp41 to prevent fusion of virus and cell membrane
used for advanced drug resistance
NO ACTIVITY AGAISNT HIV-2
entry inhibitor: ibalizumab- uiyk 2018
binds to cd4 domain 2
used for multidrug resistant HIV-1
entry inhibitor: fostemsavir 2020
binds to gp120
tx multidrug resistant HIV-1
NRTI
lack 3-0H grp
stop DNA chain growth
Toxic NRTI
zidovudine
stavudine
didanosine
less toxic NRTI
tenofovir
lamivudine
emtricitabine
abacavir *HLB 5701
T/F NRTI cause mitochondrial toxicity; Lactic acidosis, peripheral neuropathy, hepatic steatosis, pancreatitis, lipoatrophy
true
what is the most common S/E for zidovudine
myelosuppression
anemia
neutropenia
didanosine S/E
dose limiting peripheral neuropathy
what drug also treats HBV but not recommended anymore
lamivudine
which NRTI is potent monotherapy for HBV
tenofovir
what inhibits HBV and HIV reverse transcriptase
emtricitabine
2 NRTI 1 PI
NRTI
tenofovir
emtricitabine
PI
ritonavir
darunavir
2 NRTI 1 Integrase Inhibitor
NRTS
tenofovir
emtricitabine
Integrase inhibitor
raltegravir
dolutegravir
elvietgravir
NNRTI
non-competitive
adjacent to active site inducing conformation change
NNRTI drugs
Efavirenz
Nevirapine
Etravirine
Rilpivirine
Doravirine
which NNRTIs are a potent inducer of CYP450
efavirenz
nevirapine
etravirine
NNRTI: efavirenz
S/E
CNS clouding
teratogenic
which NNRTI is used in pts who've never taken HIV drugs
doravirine
fixed dose Delstrigo
Protease inhibitor drugs
-navir
atazanavir
darunavir
fosamprenavir
indinavir
lopinavir
nelfinavir
ritonavir
saquinavir
tipranavir
PI moa
block post translational maturation of viral proteinds
which PI is metabolic booster and CYP450 inhibitor
ritonavir
t/f all PI are substrates for CYP34A
true
PI S/E
hyperglycemia
hypertriglyceridemia
hypercholesterolemia
integrase inhibitors
- gravir
Raltegravir
Elvitegravir
Dolutegravir
Bictegravir
carnotegravir
which drug does not have antiviral activity and inhibits CYP450
cobicistat
cd4 cells
lymphocyte T cells that detect intruders
CD4 cell count of uninfected/healthy person
500-1,600 cells/mm3
CD4 cell count of stage 3 AIDS
< 200 cells/mm3
what is used to determine when ART therapy needs to start
CD4 count
HAART regimens
2 NRTI + 1 NNRTI/PI/INSTI
preferred regimens HAART
tenofovir/emtricitabine + raltegravir
tenofovir/emtricitabine + dolutegravir
abacavir/lamivudine + dolutegravir (HLB 5701 -)
tenofovir/emtricitabine + elvitegravir + cobicistat (good kidney function)
tenofovir/emtricitabine + ritonavir + darunavir
a 28 year old male homosexual graduate student is newly diagnosed with HIV. His CD4 count is 720 cell/mm3 and his viral load is 33, copies. would you start him on a ART therapy?
YES
which regimen would you recommend as 1st line
a/ abacavir/lamivudine/dolutegravir
b/ emtricitabine/tenofovir/efavirenz
c/ abacavir/tenofovir/lamivudine
d/ emtricitabine/tenofovir/maraviroc
a/ abacavir/lamivudine/dolutegravir
a patient who tested + for HIV arrives at clinic with fever, nonreproductive cough, and fatigue. CD4 count is 184 cell/mm3. What is findings
a/ patient has AIDS
b/ patient in latent stages of HIV
c/ patient tested + for HIV
a/ patient has AIDS
moa for maraviroc
a/ prevents virus entry
b/ cellular membrane of virus disrupted
c/ viral synthesis disrupted
a/ prevents virus entry
PI that inhibits CYO3A4 and combined with other PI to reduce pill numbers
a/ didanosine
b/ delviridine
c/ efavirenz
d/ ritonavir
d/ ritonavir
lopinavir + ritonavir + zidovudine plus ___
a/ atazanavir
b/ efavirenz
c/ lamivudine
d/ nevirapine
c/ lamivudine
one should not combine stavudine with ___
a/ atazanavir
b/ zidovudine
c/ lamivudine
b/ zidovudine
S/E for PI
a/ insulin resistance/hyperlipidemia
b/ lactic acidosis
c/ pancreatitis
d/ peripheral neuropathy
a/ insulin resistance/hyperlipidemia
NRTI have peripheral neuropathy, pancreatitis, myopathy, cardiomyopathy and lactic acidosis is ___
mitochondrial toxicity
a drug that inhibits reverse transcriptase, but does not require intracellular activation and binds to different site on RT
nevirapine